Amryt Pharma plc (AMYT)
- GlobeNewswire
Amryt to Report Q2 2021 Results and Host Conference Call & Webcast on August 6
Amryt to Report Q2 2021 Results and Host Conference Call & Webcast on August 6 DUBLIN, Ireland, and Boston MA, July 12, 2021, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases, today announces that its unaudited financial results for the second quarter 2021 will be released on Friday, August 6, 2021 at 0700 EDT/1200 BST. Amryt will host a conference call and webcast for a
- GlobeNewswire
Publication of Circular to Amryt Shareholders in relation to the acquisition of Chiasma, Inc., and posting of Annual Report and Notices of General Meetings
Publication of Circular to Amryt Shareholders in relation to the acquisition of Chiasma, Inc., and posting of Annual Report and Notices of General Meetings DUBLIN, Ireland, and Boston MA, 28 June 2021, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases (the “Company” or “Amryt”), is pleased to announce that: further to the Company's announcement on 5 May 2021 in relation t
- GlobeNewswire
Amryt Pharma Announces Filing of Preliminary Registration Statement on Form F-4 in Connection with Its Proposed Acquisition of Chiasma, Inc.
Amryt Pharma Announces Filing of Preliminary Registration Statement on Form F-4 in Connection with Its Proposed Acquisition of Chiasma, Inc. DUBLIN, Ireland, and Boston MA, June 15, 2021, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases, today announces it has filed a registration statement on Form F-4 (the "Registration Statement"), which contains a preliminary proxy st
